Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Change in Receivables: 2017-2025

Historic Change in Receivables for Cidara Therapeutics (CDTX) over the last 5 years, with Sep 2025 value amounting to $2,000.

  • Cidara Therapeutics' Change in Receivables rose 100.31% to $2,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$488,000, marking a year-over-year increase of 59.40%. This contributed to the annual value of -$14.3 million for FY2024, which is 237.09% down from last year.
  • As of Q3 2025, Cidara Therapeutics' Change in Receivables stood at $2,000, which was down 98.79% from $165,000 recorded in Q2 2025.
  • In the past 5 years, Cidara Therapeutics' Change in Receivables ranged from a high of $20.3 million in Q1 2023 and a low of -$20.6 million during Q2 2023.
  • In the last 3 years, Cidara Therapeutics' Change in Receivables had a median value of -$327,500 in 2024 and averaged -$369,500.
  • Examining YoY changes over the last 5 years, Cidara Therapeutics' Change in Receivables showed a top increase of 2,240.14% in 2021 and a maximum decrease of 3,736.48% in 2021.
  • Over the past 5 years, Cidara Therapeutics' Change in Receivables (Quarterly) stood at $1.5 million in 2021, then tumbled by 46.70% to $791,000 in 2022, then skyrocketed by 1,552.09% to $13.1 million in 2023, then plummeted by 100.04% to -$5,000 in 2024, then skyrocketed by 100.31% to $2,000 in 2025.
  • Its Change in Receivables stands at $2,000 for Q3 2025, versus $165,000 for Q2 2025 and -$5,000 for Q4 2024.